Last updated: February 24, 2026
What Is NDC 00832-0540?
NDC 00832-0540 refers to Nusinersen (brand name Spinraza), an antisense oligonucleotide developed by Biogen. It is approved for treating spinal muscular atrophy (SMA). Approved by the FDA in December 2016, Spinraza became the first approved therapy for SMA.
Market Overview
Market Size and Prevalence
- SMA affects approximately 1 in 10,000 live births worldwide.
- Estimated US diagnosed population exceeds 8,000 patients, with pediatric and adult subpopulations.
- The US SMA market was valued at around $1.1 billion in 2022, with projections reaching approximately $1.45 billion by 2027.
Competitive Landscape
| Drug Name |
Approval Year |
Mechanism |
Formulation |
Key Competitors |
| Spinraza |
2016 |
Antisense oligonucleotide |
Intrathecal |
Zolgensma, Evrysdi |
| Zolgensma |
2019 |
Gene therapy |
IV infusion |
Spinraza |
| Evrysdi |
2020 |
RNA splicing modifier |
Oral |
Spinraza |
Spinraza maintains a significant market share due to its established safety and efficacy profile, particularly in pediatric populations.
Market Drivers
- Increasing diagnosis rates through newborn screening
- Expanding approvals for different age groups
- Increased awareness and access to genetic testing
- Reimbursement policies supporting SMA treatment
Challenges
- High costs of therapy (~$750,000 per year)
- Delivery method limitations (intrathecal injections in Spinraza)
- Emergence of new therapies with simplified administration
Price Projections
Historical Pricing
- Initial US list price for Spinraza was approximately $125,000 per dose.
- Typical dosing schedule involves four loading doses in the first 2 months, then maintenance doses every four months.
- Estimated annual treatment cost per patient exceeds $750,000, considering dosing frequency.
Projected Pricing Trends
| Year |
Price per Dose (USD) |
Estimated Annual Cost (USD) |
Rationale |
| 2023 |
$125,000 |
$750,000 |
Current market; no significant price changes |
| 2024 |
$125,000 |
$750,000 |
No new competitors impacting pricing |
| 2025 |
$125,000 |
$700,000 - $750,000 |
Potential negotiations or payer discounts |
| 2026 |
$125,000 |
$700,000 - $750,000 |
Competition from biosimilars or improved therapies |
Influence Factors
- Biosimilar and alternative therapies: None currently approved for SMA but their emergence could pressure prices downward.
- Cost containment policies: Payers seeking price reductions could impact list prices or reimbursement terms.
- Biogen's pricing strategies: May involve discounts or patient assistance programs to maintain market share.
Future Outlook
- The entry of gene and mRNA-based therapies could reduce demand, exerting downward pressure on prices.
- Potential for price stabilization if new indications or expanded payer coverage occur.
- Price adjustments in response to healthcare policy changes, especially concerning high-cost treatments.
Key Takeaways
- Spinraza remains a dominant SMA treatment with an approximate annual cost of $750,000 per patient.
- The market is constrained by high costs, administration challenges, and emerging competitors.
- Pricing is expected to stabilize unless disruptive therapies enter the market or policy pressures induce reductions.
- US and European markets continue to expand as diagnosis and treatment access improve.
- Future developments in gene therapies may influence pricing and market share dynamics.
FAQs
1. How does the price of Spinraza compare to alternative SMA therapies?
Spinraza's list price is higher than Evrysdi, which costs approximately $340,000 annually, but Zolgensma, a gene therapy, is a one-time infusion priced at roughly $2.1 million.
2. Are there pricing trends for biosimilars or generics for Spinraza?
No biosimilars or generics are approved for Spinraza as of 2023. Biosimilars could enter the market post-patent expiry, potentially reducing prices.
3. What are the reimbursement trends for SMA treatments?
Insurance coverage varies, with payers often requiring prior authorization. Reimbursement negotiations influence actual patient costs and access.
4. How might regulatory changes impact pricing?
Healthcare policies targeting high-cost specialty drugs could lead to price negotiations, discounts, or value-based pricing models.
5. What future market factors could influence pricing?
Introduction of more convenient administration methods, broader indication approvals, or new therapeutic classes could shift market dynamics and pricing.
References
[1] FDA. (2016). Spinraza approval for spinal muscular atrophy.
[2] Biogen. (2022). Spinraza prescribing information.
[3] IQVIA. (2022). Global SMA market report.
[4] SSR Health. (2023). Biogen pricing overview.
[5] National Institutes of Health. (2020). Prevalence of SMA and diagnostic trends.
